Ocular Therapeutix Gross Profit Growth & History (OCUL)
Ocular Therapeutix's gross profit was $45.4M for fiscal 2025.
View full Ocular Therapeutix company overviewOcular Therapeutix annual gross profit history
| Fiscal year | Period ended | Gross profit | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $45.4M | −$12.7M | −21.89% |
| 2024 | 2024-12-31 | $58.1M | $4.9M | +9.28% |
| 2023 | 2023-12-31 | $53.2M | $6.2M | +13.22% |
| 2022 | 2022-12-31 | $47.0M | $7.8M | +20.04% |
| 2021 | 2021-12-31 | $39.1M | $23.8M | +155.33% |
| 2020 | 2020-12-31 | $15.3M | $13.4M | +705.47% |
| 2019 | 2019-12-31 | $1.9M | $377,000 | +24.72% |
| 2018 | 2018-12-31 | $1.5M | $59,000 | +4.02% |
| 2017 | 2017-12-31 | $1.5M | $22,000 | +1.52% |
| 2016 | 2016-12-31 | $1.4M | $13,000 | +0.91% |
| 2015 | 2015-12-31 | $1.4M | $750,000 | +110.13% |
| 2014 | 2014-12-31 | $681,000 | — | — |
| 2012 | 2012-12-31 | $3,000 | — | — |
Ocular Therapeutix quarterly gross profit
| Fiscal quarter | Period ended | Gross profit | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $11.5M | −$51,000 | −0.44% |
| Q1 2026 | 2026-03-31 | $9.5M | $20,000 | +0.21% |
| Q4 2025 | 2025-12-31 | $11.7M | −$4.2M | −26.47% |
| Q3 2025 | 2025-09-30 | $12.8M | −$1.1M | −7.89% |
| Q2 2025 | 2025-06-30 | $11.5M | −$3.4M | −22.88% |
| Q1 2025 | 2025-03-31 | $9.4M | −$4.0M | −29.83% |
| Q4 2024 | 2024-12-31 | $15.9M | $2.4M | +18.16% |
| Q3 2024 | 2024-09-30 | $13.9M | $160,000 | +1.17% |
| Q2 2024 | 2024-06-30 | $14.9M | $1.1M | +7.56% |
| Q1 2024 | 2024-03-31 | $13.4M | $1.3M | +10.59% |
| Q4 2023 | 2023-12-31 | $13.4M | $352,000 | +2.69% |
| Q3 2023 | 2023-09-30 | $13.7M | $2.8M | +25.82% |
| Q2 2023 | 2023-06-30 | $13.9M | $2.8M | +24.94% |
| Q1 2023 | 2023-03-31 | $12.2M | $273,000 | +2.30% |
| Q4 2022 | 2022-12-31 | $13.1M | $1.9M | +16.63% |
| Q3 2022 | 2022-09-30 | $10.9M | $49,000 | +0.45% |
| Q2 2022 | 2022-06-30 | $11.1M | $489,000 | +4.60% |
| Q1 2022 | 2022-03-31 | $11.9M | $5.4M | +84.29% |
| Q4 2021 | 2021-12-31 | $11.2M | $4.5M | +67.96% |
| Q3 2021 | 2021-09-30 | $10.8M | $5.4M | +99.83% |
| Q2 2021 | 2021-06-30 | $10.6M | $9.2M | +640.21% |
| Q1 2021 | 2021-03-31 | $6.5M | $4.7M | +260.34% |
| Q4 2020 | 2020-12-31 | $6.7M | $5.3M | +370.64% |
| Q3 2020 | 2020-09-30 | $5.4M | $5.4M | +23491.30% |
| Q2 2020 | 2020-06-30 | $1.4M | $1.3M | +1364.29% |
| Q1 2020 | 2020-03-31 | $1.8M | $1.4M | +391.76% |
| Q4 2019 | 2019-12-31 | $1.4M | $1.0M | +266.15% |
| Q3 2019 | 2019-09-30 | $23,000 | −$360,000 | −93.99% |
| Q2 2019 | 2019-06-30 | $98,000 | −$397,000 | −80.20% |
| Q1 2019 | 2019-03-31 | $364,000 | $104,000 | +40.00% |
| Q4 2018 | 2018-12-31 | $387,000 | $13,000 | +3.48% |
| Q3 2018 | 2018-09-30 | $383,000 | −$15,000 | −3.77% |
| Q2 2018 | 2018-06-30 | $495,000 | $161,000 | +48.20% |
| Q1 2018 | 2018-03-31 | $260,000 | −$100,000 | −27.78% |
| Q4 2017 | 2017-12-31 | $374,000 | −$10,000 | −2.60% |
| Q3 2017 | 2017-09-30 | $398,000 | $33,000 | +9.04% |
| Q2 2017 | 2017-06-30 | $334,000 | −$2,000 | −0.60% |
| Q1 2017 | 2017-03-31 | $360,000 | $1,000 | +0.28% |
| Q4 2016 | 2016-12-31 | $384,000 | $40,000 | +11.63% |
| Q3 2016 | 2016-09-30 | $365,000 | $27,000 | +7.99% |
| Q2 2016 | 2016-06-30 | $336,000 | −$43,000 | −11.35% |
| Q1 2016 | 2016-03-31 | $359,000 | −$11,000 | −2.97% |
| Q4 2015 | 2015-12-31 | $344,000 | −$131,000 | −27.58% |
| Q3 2015 | 2015-09-30 | $338,000 | $227,000 | +204.50% |
| Q2 2015 | 2015-06-30 | $379,000 | $302,000 | +392.21% |
| Q1 2015 | 2015-03-31 | $370,000 | $352,000 | +1955.56% |
| Q4 2014 | 2014-12-31 | $475,000 | — | — |
| Q3 2014 | 2014-09-30 | $111,000 | — | — |
| Q2 2014 | 2014-06-30 | $77,000 | — | — |
| Q1 2014 | 2014-03-31 | $18,000 | — | — |
Ocular Therapeutix gross profit trends
Over the last five fiscal years, Ocular Therapeutix's gross profit increased from $15.3M to $45.4M, a change of $30.1M. The latest reported quarter, Q2 2026, shows $11.5M.
What gross profit means
Gross profit is the amount of revenue remaining after the direct costs of producing and delivering a company’s goods or services. It helps show the dollars available to cover operating expenses before operating income, interest, and taxes.
SEC-reported and calculated gross profit
TickerStat uses gross profit reported in company SEC filings when available. Otherwise, it calculates gross profit as SEC-reported revenue minus aligned cost of revenue for the same fiscal period. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Ocular Therapeutix source filings ↗